FDA Advisory Committee OKs Marketing Use of Three Psych Meds for Youth

An expert panel for the U.S. Food and Drug Administration (FDA) has approved the marketing of three psychotropic medications for use by mentally disturbed youth, a path of treatment that is already heavily relied upon by some child welfare and juvenile justice systems.

The Psychopharmacologic Drugs Advisory Committee said this month that it supports a request by the manufacturers of Zyprexa, Seroquel and Geodon to market the drugs as effective and acceptably safe for treatment of bipolar disorder and schizophrenia among youth.

The decision to approve the drugs now rests with the FDA, an action which some observers believe that approval could lead to more prescriptions for the drugs to youth.

Here are the three drugs up for discussion, their makers and the prescribed use for which the maker sought approval:

Zyprexa. Eli Lilly. “For the acute treatment of manic or mixed episodes associated with bipolar I disorder and the acute treatment of schizophrenia in adolescents.” Lilly agreed to pay the U.S. government $1.4 billion to settle criminal and civil cases regarding its promotion of Zyprexa for use with the elderly and children. Zyprexa is one of the three drugs that was prescribed to Gabriel Myers, a 7-year-old Florida foster child who is believed to have committed suicide. Myers’ death prompted the Florida Department of Children and Families to examine the use of psychotropic medication by children in the agency’s care.

Seroquel: AstroZeneca. “For the acute treatment of schizophrenia in adolescents from 13 to 17 years of age, and the acute treatment of bipolar mania in children from 10 to 12 years of age and adolescents from 13 to 17 years of age.” 

Geodon: Pfizer. “For the acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features in children and adolescents ages from 10 to 17 years of age.”

What Could Change

Doctors are not prohibited from prescribing the medications to youths now, but must do so off-label. Informal studies have yielded some positive results in youths, but the side effects of these three drugs and others in the “atypical antipsychotics” family include significant weight gain and Type II diabetes.

Official approval to market the drugs might ease concerns of state Medicaid and Medicare agencies about paying for the drugs, said David Cohen, a psychotherapist and professor at Florida International University.

“The bulk of sales [for psychotropic drugs] have been from government programs,” namely  Medicaid and Medicare, Cohen said. It is possible that state Medicaid agencies, which are directly involved in expenditures for youths in the child welfare system, “will lessen their scrutiny of the drugs if they’re approved.”

“I believe the approval, should it officially come from the FDA, will counter the very recent drop in sales,” said Cohen.

Psychologist Ronald Brown, who made a statement to the committee on behalf of the American Psychological Association, indicated that an association working group on such drugs yielded little evidence that they were successful in treating youth, while there was little doubt that they carried significant risk of serious side effects. Brown did not ask the committee to reject the applications.

“Of the few pediatric studies that do exist, many include small samples sizes and attendant methodological weaknesses,” said Brown, the dean of public health at Temple University.

Speaking with health trade paper HealthDay before the committee voted, however, Brown said his own view was that the applications should not be approved.

“Particularly with children, when you don’t know, I don’t think you should approve it,” Brown said. “In this country, we are very overzealous to approve drugs. I think we need to be more conservative, particularly because this is a pediatric population.”

The use of psychotropic medications is high among youth involved in state systems such as child welfare and juvenile justice. About 14 percent of youth in foster care are prescribed a psychotropic medication, according to a policy paper written in 2006 by the Institute for Juvenile

Research at the University of Illinois at Chicago. But only 1 to 3 percent all youth suffer from bipolar disorder and schizophrenia, according to Dr. David Fassler, a clinical professor of psychiatry at the University of Vermont College of Medicine.


Youth Today is the only independent, internationally distributed digital media publication that is read by thousands of professionals in the youth service field.

Youth Today adheres to high-quality journalistic standards, providing readers with professional news coverage dedicated to examining a wide spectrum of complex issues in the youth services industry from legislation to community-based youth work.


Our organization retains full authority over editorial content to protect the best journalistic and business interests of our organization. We maintain a firewall between news coverage decisions and sources of all revenue.


We are committed to transparency in every aspect of funding our organization. Donors may be quoted, mentioned or featured in our stories. Our news judgments are made independently – not based on or influenced by donors. Accepting financial support does not mean we endorse donors or their products, services or opinions…(read more)

Recent Comments




Kennesaw State University Mountain Logo & Ceneter for Sustainable Journalism Logo
LOGO Institute for Nonprofit News 3 turquoise boxes stacked in "J" shape

Copyright © 2018 Youth Today and MVP Themes --- Published by Center for Sustainable Journalism,
Kennesaw State University, 1200 Chastain Blvd. Suite 310, Kennesaw GA 30144

To Top